Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• AMD3
• Clinical Trials3
• Wet Amd3
• Injections2
• Retina2
• Gene Therapy1

• Organizations: RegenxBio✕

Clear all

Pipeline

RegenxBio reports positive phase 2 bilateral wet AMD data

Nine-month clinical findings noted a 97% reduction in treatment burden following subretinal delivery of gene therapy treatment.

Pipeline

REGENXBIO shares 2-year data on gene therapy injection for wet AMD

Dose-escalation study reports stable or improved vision and retinal anatomy up to 2 years.

Pipeline

RegenxBio reports positive interim data in gene therapy trial for wet AMD

Phase 2 AAVIATE study is evaluating ABBV-RGX-314 as a one-time, subretinal injection.